FIRST TRACKS BIOTHERAPEUTICS, INC. Research and Development Expense
FIRST TRACKS BIOTHERAPEUTICS, INC. (TRAX) reported Research and Development Expense of $25.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- FIRST TRACKS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $25.64M, a 34.70% decline year-over-year.
- FIRST TRACKS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $33.95M, a 18.11% decline year-over-year.
- FIRST TRACKS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $39.27M.
- FIRST TRACKS BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-03-31 was $41.47M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $25.64M 10-Q · filed 2026-08-12 | $59.60M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $33.95M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $39.27M 10-Q · filed 2026-08-12 | $80.74M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $41.47M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |